In a groundbreaking moment for medical cannabis in the UK, patients made history on November 7, 2025, by medicating and vaping within the hallowed halls of The Charterhouse in London. This patient-led educational event, a first in the venue’s 650-year history, marked a significant step forward in normalizing and advancing the conversation around cannabis-based medicines.
A Venue Steeped in History Hosts a Modern Milestone
The Charterhouse, a historic site with origins dating back to the bubonic plague pandemic of 1348, has witnessed centuries of London’s evolution. Its transformation from a medieval monastery to a pioneering charity in 1611 made the decision to allow patients to consume their prescribed cannabis-based medicines within its walls a deeply symbolic act. This historic allowance underscores a shift in perception and acceptance, paving the way for future patient-centered medical cannabis events.
Pioneering Patient Advocacy and Education
The event was meticulously organized by two prominent patient advocacy groups: the international organization ‘We, The Patients,’ chaired by Carola Pérez, and the UK-based ‘PatientsCann UK,’ led by Mohammad Wasway. These groups are at the forefront of reshaping the dialogue surrounding medical cannabis in Europe, striving to build bridges of understanding between patients, healthcare professionals, and policymakers. Their collaborative efforts aim to foster trust, community, and evidence-based education, a mission amplified by this unique London gathering. Previous successful events by ‘We, The Patients’ in Bern, Madrid, and Zurich have laid the groundwork for this landmark London initiative, which coincided with Medical Cannabis Awareness Week.
Expert Insights on Research and Real-World Evidence
The event featured a distinguished line-up of medical and scientific experts. Dr. Mikael Sodergren, Head of Imperial College London’s Medical Cannabis Research Group and Chief Medical Officer at Curaleaf International, delivered a compelling presentation. He highlighted the critical role of real-world evidence (RWE) collection, particularly through the UK Medical Cannabis Registry, which now boasts over 50,000 enrolled patients. Dr. Sodergren’s research team is leveraging Artificial Intelligence (AI) to analyze this vast dataset, aiming to predict treatment outcomes, identify optimal cannabinoid combinations, and profile patient characteristics for more personalized therapeutic approaches. His work emphasizes the scientific validation required to support the growing use of cannabis-based medicines, acknowledging that the medical profession is still adapting to this evolving field.
Other speakers included Dr. Rowan Thompson, who discussed the endocannabinoid system, Dr. Sameen Jalil, who explored methods of administration, and patient advocate Julie Durrans, who shared powerful lived experiences. Practical workshops on vaporization techniques and the therapeutic potential of terpenes were also featured, offering attendees hands-on learning opportunities.
The Patient Voice at the Forefront
The patient-led nature of the event was central to its success. By empowering patients to lead discussions and share their experiences alongside medical experts, the organizers created a unique environment of empathy and mutual learning. This approach is vital for reducing the stigma still associated with medical cannabis and for ensuring that research and policy development are truly patient-centered. The event served as a platform for patients to connect, share knowledge, and find strength in community.
A Growing Landscape for Medical Cannabis in the UK
This historic event takes place against a backdrop of significant developments in the UK’s medical cannabis sector. While awareness is growing, and patient numbers in private clinics continue to rise, access through the NHS remains limited. Trending discussions in 2025 have focused on the ongoing government review of the 2018 medical cannabis reforms, the increasing importance of real-world evidence, and the growing number of cannabis-focused educational events and symposia aimed at healthcare professionals. The success of this patient-led event underscores the demand for accessible, evidence-based information and the critical need for continued dialogue to advance patient care and research in the UK.
Looking Ahead
The gathering at The Charterhouse represents more than just a single event; it is a testament to the growing momentum behind medical cannabis in the UK. By bringing together patients, clinicians, and researchers in such a historic setting, ‘We, The Patients’ and ‘PatientsCann UK’ have underscored the potential for collaboration and innovation. As the UK navigates evolving policies and continues to build its evidence base, events like these are crucial for shaping a future where cannabis-based medicines are understood, accessible, and integrated responsibly into patient care.
